Luminita Mann
Nurse Practitioner · Fullerton, CANPI 1326338450
Payments from drug & device makers
Across 511 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Novo Nordisk$1K
- Dexcom, Inc.$674
- Sanofi-aventis U.S. LLC$656
- AstraZeneca$539
- Amgen$531
- plus $4K from 34 others
What the payments were for
- Speaking & faculty fees$4054%
- Food & beverage$9,21396%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 114 | $2,070 |
| Novo Nordisk | 75 | $1,139 |
| Dexcom, Inc. | 39 | $674 |
| Sanofi-aventis U.S. LLC | 12 | $656 |
| AstraZeneca(2 entities) | 28 | $539 |
| Amgen(2 entities) | 34 | $531 |
| Abbott | 29 | $485 |
| Boehringer Ingelheim | 24 | $466 |
| Corcept Therapeutics | 13 | $377 |
| AbbVie | 18 | $357 |
| Insulet Corporation | 21 | $275 |
| Bayer | 12 | $229 |
| IBSA Pharma Inc. | 18 | $210 |
| Radius Health, Inc. | 9 | $208 |
| Novartis | 9 | $190 |
| Medtronic | 6 | $114 |
| GRT US Holding, Inc. | 4 | $112 |
| Tandem Diabetes Care, Inc. | 5 | $96 |
| Embecta Corp. | 3 | $90 |
| Lifescan, Inc. | 4 | $87 |
| Xeris Pharmaceuticals, Inc. | 4 | $86 |
| Amarin Pharma, Inc. | 4 | $84 |
| Recordati_rare_diseases_inc. | 3 | $83 |
| BD | 2 | $61 |
| Madrigal Pharmaceuticals | 2 | $49 |
| Mannkind Corporation | 3 | $45 |
| Bigfoot Biomedical Inc | 2 | $43 |
| Rhythm Pharmaceuticals, Inc. | 2 | $39 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Averitas Pharma Inc. | 1 | $27 |
| Cequr Corporation | 1 | $24 |
| Astellas Pharma US Inc | 1 | $24 |
| Sequel Med Tech, LLC | 1 | $21 |
| Antares Pharma, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Pfizer | 1 | $18 |
| Merck | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Amryt Pharma Holdings Ltd | 1 | $13 |
| Ascensia Diabetes Care US Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$350
- Wegovy$125
How this compares
$9,630 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 476 | $771,613 |
| MounjaroTirzepatide | 352 | $457,658 |
| JardianceEmpagliflozin | 312 | $390,229 |
| TrulicityDulaglutide | 166 | $234,414 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 156 | $151,967 |
| FarxigaDapagliflozin Propanediol | 136 | $138,974 |
| JanuviaSitagliptin Phosphate | 91 | $124,453 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 118 | $86,869 |
| TradjentaLinagliptin | 47 | $64,510 |
| Tresiba Flextouch U-100Insulin Degludec | 87 | $62,008 |
| Humalog Kwikpen U-100Insulin Lispro | 159 | $57,076 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 275 | $46,433 |
| RybelsusSemaglutide | 24 | $38,451 |
| Humalog Kwikpen U-200Insulin Lispro | 21 | $36,804 |
| Tresiba Flextouch U-200Insulin Degludec | 40 | $32,515 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,139 | $810,064500 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $2,070 | $708,966563 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $466 | $468,111371 claims |
| MerckJanuvia, Janumet, Janumet Xr | $17 | $168,321138 claims |
| AstraZenecaFarxiga | $539 | $138,974136 claims |
| AbbVieSynthroid | $357 | $10,355111 claims |
| Sanofi-aventis U.S. LLCLantus | $656 | $10,28250 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Fullerton
- Jill OlmsteadFullerton$24K
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.